AFP and hepatocellular carcinoma: This could relate to an improvement in specificity in a clinical scenario, for example, if the specificity is recalculated to account for a 2.40% prevalence of HCC in the NCCLD cohort [38], specificity would rise to 90.54% for the TA-AAb panel and 91.00% for the TA-AAb plus AFP panel.